GlaxoSmithKline News and Research

RSS

London Ranked Top City in Europe for Life Sciences

A newly released report has named London the #1 city in Europe and #3 globally for life sciences, behind Boston and New York, and ahead of Amsterdam, Munich, Paris, San Francisco, and Singapore.

18 Nov 2024

Small RNA-Binding Protein Promotes Prime Editing Efficiency

Through years of engineering gene-editing systems, researchers have developed a suite of tools that enable the modification of genomes in living cells, akin to 'genome surgery'.

23 Apr 2024

Unveiling the Potential of the New Antibiotics Against Bacteria

A novel family of antibiotics with strong action against bacteria resistant to many drugs has been found by Uppsala University researchers, and they have demonstrated that this class of antibiotics may treat bloodstream infections in mice.

2 Apr 2024

Boosting Post-Transplant Survival: Tailoring Gut Microbiome to Fight GvHD

After stem cell transplantation, the donated immune cells sometimes attack the patients' bodies. This is known as graft versus host disease or GvHD.

9 Jan 2024

Study Cracks Open the Enigma of Major Evolutionary Leaps

Significant evolutionary changes happen gradually as opposed to in dramatic 'monster' steps, biologists have discovered, answering the long-debated question as to how game-changing innovations like flight, vision, and the bearing of live offspring came to be.

5 Jan 2024

Study Reveals an Immunological Strategy to Overcome Microbiome-Related Immunotherapy Resistance

Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.

4 May 2023

Scientists discover mechanism behind how plants can develop long-term immunity to stress

A mechanism behind how plants can develop long-term immunity to stress has been discovered by scientists at the University of Sheffield.

8 Mar 2023

Challenges in Drug Discovery; Where are we now, and where are we going?

As part of our SLAS Europe 2022 coverage, we speak to Steve Rees, Vice-President of Discovery Biology at AstraZeneca, about the challenges currently faced by the drug discovery sector.

From Society for Laboratory Automation and Screening (SLAS) 8 Jul 2022

New reports highlight the resilience of local food sector during the Covid-19 pandemic

Local food suppliers saved the day during the Covid-19 pandemic food shortages, but new research from the University of Sheffield also finds lessons need to be learned if national food systems are to survive future crises.

9 May 2022

Researchers discover new type of cell that may play a key role in human lung diseases

A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

4 Apr 2022

Specific gene variant linked with poor response to sublingual immunotherapy for allergies

Although sublingual immunotherapy (SLIT) has become an effective treatment option for many allergies, about 20-30% of patients don’t respond to SLIT for Japanese cedar pollinosis–a highly common disease.

8 Mar 2022

Experts trigger apoptosis in leukemia cells by disrupting their energy maintenance mechanism

A group of researchers from UNIGE in Switzerland and Inserm in France has discovered a previously unknown process that could lead to the creation of novel medicines.

18 Feb 2022

Next-generation sequencing for minimal residual disease proven more sensitive than flow cytometry

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

2 Dec 2021

Researchers map proteo-genomic connections between different human diseases

Hundreds of connections between different human diseases have been uncovered through their shared origin in our genome by an international research team led by scientists from the Medical Research Council (MRC) Epidemiology Unit at the University of Cambridge, challenging the categorisation of diseases by organ, symptoms, or clinical speciality.

18 Oct 2021

New datasets published to better train ML models for drug discovery

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GSK) and the Cambridge Crystallographic Data Centre (CCDC) combined their proprietary (GSK) and published (CCDC) datasets to better train machine learning (ML) models to predict stable polymorphs to use in new drug candidates.

4 Oct 2021

Scientists discover genes responsible for smoking-related decline in lung function

(Boston)--Chronic Obstructive Pulmonary Disease (COPD) is a disease caused by cigarette smoking that reduces lung function and causes difficulty breathing.

12 May 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Many light smokers meet the criteria for nicotine addiction

Even people who consider themselves to be casual cigarette smokers may be addicted, according to current diagnostic criteria. Researchers at Penn State College of Medicine and Duke University found that many light smokers -- those who smoke one to four cigarettes per day or fewer -- meet the criteria for nicotine addiction and should therefore be considered for treatment.

24 Dec 2020

New data shows immunotherapy is beneficial for patients with gastric, esophageal cancers

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival. (1-3)

24 Sep 2020

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.